Heart Health
SGLT2 Inhibitors Deliver Far More Than Blood Sugar Control
A major review reveals how SGLT2 inhibitors protect the heart, kidneys, and metabolism through at least seven distinct biological mechanisms.
Research Paper
May 12, 2026 0
Results for "SGLT2 Inhibitors"
20 articles
Metabolic Health
SGLT2 Inhibitors May Shield Kidneys From Acute Injury Through Multiple Mechanisms
A comprehensive review finds SGLT2 inhibitors reduce AKI risk in humans via hemodynamic, metabolic, and cellular protective pathways.
Research Paper
May 12, 2026 0
Metabolic Health
SGLT2 Inhibitors May Slow Aging by Clearing Senescent Cells
Diabetes drugs like empagliflozin show surprising anti-aging effects — mimicking caloric restriction and reducing senescent cell burden.
Research Paper
May 15, 2026 0
Heart Health
Premium
Vascular Rejuvenation: Advanced Interventions to Reverse Arterial Aging
Dive deep into the molecular mechanisms of vascular aging and explore cutting-edge interventions — from senolytic therapies and nitric oxide restoration to exercise-induced remodeling and emerging pharmacological approaches — that are redefining what's possible in cardiovascular longevity.
TutorialAdvanced
May 2, 2026 0
Metabolic Health
SGLT2 Inhibitors May Not Benefit Lean Non-Diabetic CKD Patients
Landmark CKD trials enrolled mostly overweight patients — new evidence questions whether SGLT2 inhibitors work for lean, non-diabetic individuals.
Research Paper
May 12, 2026 0
Metabolic Health
GLP-1 and SGLT-2 Drug Combo Hits Glucose Targets in 42% of Type 2 Diabetics
A real-world study of 549 patients finds that combining GLP-1 receptor agonists with SGLT-2 inhibitors meaningfully improves glucose control — and baseline HbA1c predicts who benefits most.
Research Paper
Jun 27, 2026 0
Metabolic Health
SGLT2 Inhibitor Dapagliflozin Reshapes Metabolism Beyond Blood Sugar Control
New study reveals how the diabetes drug dapagliflozin dramatically alters fat metabolism and kidney function through previously unknown pathways.
Research Paper
Apr 9, 2026 0
Longevity & Aging
GLP-1 Drugs Linked to Lower Diabetic Foot Amputation Risk Than SGLT2 Inhibitors
Real-world data shows GLP-1 users had significantly lower odds of foot ulcers, bone infections, and amputations compared to SGLT2 inhibitor users.
Press Release
Jun 14, 2026 0
Heart Health
SGLT2 Inhibitors Cut Death and Heart Failure Risk Even in Patients Over 80
Real-world study of 1,559 octogenarians finds SGLT2 inhibitors reduce all-cause death by 42% and heart failure rehospitalization by 31% with no increase in adverse events.
Research Paper
May 12, 2026 0
Longevity & Aging
Oral Semaglutide Reduces Heart Disease Risk Even When Combined with SGLT2 Inhibitors
Major diabetes trial shows GLP-1 drugs maintain cardiovascular benefits when used alongside SGLT2 inhibitors, supporting combination therapy.
Research Paper
Apr 7, 2026 0
Longevity & Aging
Dapagliflozin Blocks Kidney Cell Death in Diabetes via Ketone Body Pathway
SGLT2 inhibitor dapagliflozin protects diabetic kidneys by raising β-hydroxybutyrate and suppressing iron-driven cell death (ferroptosis).
Research Paper
May 16, 2026 0
Longevity & Aging
SGLT2 Diabetes Drugs Linked to 39% Lower Dementia Risk in People With Mood Disorders
A large VA study finds SGLT2 inhibitors cut dementia risk by nearly 40% in older adults with depression, bipolar disorder, or schizophrenia.
Press Release
Jul 1, 2026 0
Longevity & Aging
Alpha Glucosidase Inhibitors Offer Safer Blood Sugar Control for High-Risk Patients
A comprehensive review of AGIs explains how acarbose and miglitol manage type 2 diabetes while reducing hypoglycemia and lactic acidosis risks.
Research Paper
Jun 2, 2026 0
Longevity & Aging
GRADE Trial Reveals Which Diabetes Drug Cuts Hospitalizations Most
A landmark RCT of 5,047 type 2 diabetics finds GLP-1 agonists linked to fewer hospitalizations than other second-line therapies.
Research Paper
May 22, 2026 0
Metabolic Health
More Powerful GLP-1 Drugs Don't Mean More Side Effects, Major Analysis Finds
A systematic review of 38 trials finds tirzepatide cuts HbA1c nearly 3x more than lixisenatide with similar GI side effect rates.
Research Paper
Jun 4, 2026 0
Metabolic Health
GLP-1 Drugs Deliver Far More Than Blood Sugar Control, Lancet Review Finds
A landmark Lancet review reveals GLP-1 receptor agonists protect the heart, kidneys, liver, and brain — reshaping how we think about metabolic medicine.
Research Paper
May 30, 2026 0
Longevity & Aging
Ten Drug Classes Now Available to Manage Type 2 Diabetes Beyond Insulin
A comprehensive review maps every oral and injectable non-insulin option for T2DM, from metformin to dual GLP-1/GIP agonists.
Research Paper
Jun 30, 2026 0
Metabolic Health
GLP-1 Drugs Show No Extra Depression Risk vs DPP-4 Inhibitors in Large Study
A 10-year Korean cohort study finds GLP-1 receptor agonists don't raise psychiatric risk compared to DPP-4 inhibitors, but show modest signals vs SGLT2 inhibitors.
Research Paper
Jul 1, 2026 0
Metabolic Health
GLP-1 Drugs Transform Diabetes Treatment with Weight Loss and Heart Benefits
Review explores how GLP-1 receptor agonists revolutionize type 2 diabetes care through improved blood sugar control and significant weight reduction.
Research Paper
Apr 9, 2026 0
Metabolic Health
Canagliflozin Protects Against Low Sodium Diet Risks in Type 2 Diabetes
SGLT2 inhibitor canagliflozin prevents cardiovascular harm from low-sodium diets in diabetic kidney disease patients.
Research Paper
Mar 28, 2026 1
Metabolic Health
GLP-1 Drugs Show Real Promise for Obese Kids and Teens With Type 2 Diabetes
A systematic review of 13 studies finds semaglutide and liraglutide meaningfully cut BMI and improve blood sugar in children and adolescents.
Review
Jun 29, 2026 0
Page 1 of 2Next